



24 September 2024

Bioxyne Ltd Investor Webinar – Hosted by Jane Morgan Management

Pharmaceutical and consumer health products Company, Bioxyne Limited (**ASX:BXN**) (“**Bioxyne**” or the “**Company**”), is pleased to invite shareholders and prospective investors to an online investor webinar.

The webinar will be held online via Zoom on Wednesday 25th of September 2024, at 4:00pm AEST (2:00pm AWST), where Managing Director, Sam Watson, will provide an update on the Company and engage in a live Q&A session.

Event: BXN Investor Webinar

Presenter: Managing Director, Mr Sam Watson

Time: Wednesday, 25 September at 4:00 pm AEST (2:00 pm AWST)

Where: Zoom Webinar, details to be provided upon registration

To register your interest for the webinar, please click the link below, or copy/paste the URL into your browser. After registering your interest, you will receive a confirmation email with information about joining the webinar on the day.

Registration link:

https://janemorganmanagement-au.zoom.us/webinar/register/WN_BsUCII4uTLCdd4C71pBSdg

Attendees are able to submit questions for Q&A throughout the presentation to learn more about the Company. We also encourage registrants to send through questions via email beforehand to jm@janemorganmanagement.com.au

For further information, please contact:

Sam Watson

Managing Director

Bioxyne Limited

hello@breathelifesciences.com

Jane Morgan

Investor & Media Relations

Bioxyne Limited

jm@janemorganmanagement.com.au





About Bioxyne Limited:

Bioxyne Limited (ASX:BXN) is an Australian life sciences and health products business. In June 2023 Bioxyne acquired BLS in an all shares transaction becoming the parent company of Breathe Life Sciences (“BLS”) and DR Watson®. The Group, which is headquartered in Sydney and has offices in London, Manchester, Prague, Brisbane, and Nagoya, manufactures and distributes novel pharmaceuticals and consumer health products globally.

About Breathe Life Sciences:

Bioxyne Limited’s wholly owned subsidiary, Breathe Life Sciences (BLS), manufactures, commercializes, and distributes medical cannabis, psychedelics, novel foods and consumer health products under our own brands and for third party brands.

BLS’ goal is to become the market leading Australian manufacturer of novel pharmaceuticals and medicine products derived from Cannabis, Psilocybe Cubensis, and MDMA. In Australia, BLS is licensed to manufacture MDMA and Psilocybin products for commercial supply to authorised prescribers and clinical trials in Australia and global export markets. In the UK and Europe BLS is a market leader in the supply of CBD (Cannabidiol) and functional mushroom products to national retailers and Amazon. BLS manufactures private, white label, and under its own brands in its UK and EU facilities.

